The sarcopenia market remains largely untapped with no approved drug therapies in major markets, despite significant unmet medical needs in an aging global population.
The FDA has granted Fast Track designation to Lipocine's LPCN 1148 for treating sarcopenia in patients with decompensated cirrhosis, addressing an unmet medical need.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.